A Phase 3 Protocol of Total Androgen Suppression and Radiation Therapy (RT) vs. TAS and RT Followed by Chemotherapy with Paclitaxel, Estramustine, and Etoposide for Localized, High Risk, Prostate Cancer

Abstract

Summary of Protocol Objectives: The primary objectives were to assess the relative efficacy of the combination of androgen suppression (AS) plus radiation therapy (RT) followed AS vs. AS plus RT followed by chemotherapy (CT) plus AS in high risk, unfavorable prognosis prostate cancer (PCa) population. In order to measure the efficacy of the treatments the endpoints being evaluated were overall survival, disease free survival, local control and freedom from distant metastasis. Differences in toxicities between the two treatments were also going to be evaluated. The RTOG 9902 investigators hypothesize that adjuvant CT would improve the survival rate of high-risk PCa when used in combination with RT and AS. Methods: The purpose and methods were reviewed and approved by the local IRB. The voluntary and full informed consent of participants was obtained prior to study procedures. Volunteer participants who met eligibility criteria were stratified, enrolled and randomized as per protocol. In brief, eligibility criteria included men with high risk non metastatic prostate cancer histologically confirmed with PSA level of 20-100ng/mL and a Gleason score > 7, stage T2 or greater. Volunteer participants were randomized into one of two treatments. RT began 8 weeks after androgen suppression treatment and followed weekly by their radiation oncologist during the RT, every 3 months for two years, then every 6 months for three years and yearly after that for the remainder of the participant s natural life. Results: Study was locally approved on November 2000 and assigned number FDG20010007H, receiving 10 continuing approval before IRB oversight was transferred to Wilford Hall (WHMC) under protocol number FWH20110083H. IRB oversight was transferred back DGMC in May 2012. This study opened nationally in Jan 2000 and prematurely closed to accrual in Oct 2004 with a total of 397 participants (380 eligible); 2 from DGMC. The protocol has been deemed terminated by national RT

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 13, 2014
Accession Number
ADA608680

Entities

People

  • David Hoopes
  • Davis Eastham
  • Hristov Borislav
  • James Edward Mitchell
  • Ronald Engel

Organizations

  • David Grant USAF Medical Center

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Androgens
  • Cancer
  • Chemotherapy
  • Diseases And Disorders
  • Drug Therapy
  • Medical Personnel
  • Metastasis
  • Military Transfers
  • Monitoring
  • Neoplasms
  • Physicians
  • Prostate
  • Prostate Cancer
  • Radiation
  • Therapy
  • Toxicity
  • Volunteers

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Oncology (Cancer Research).
  • Prostate Cancer Biology.